文献速递免疫规划

冈比亚农村地区黄热病疫苗与13价肺炎球菌结合疫苗联合接种的免疫原性:一项整群随机试验

Immunogenicity of yellow fever vaccine co-administered with 13-valent pneumococcal conjugate vaccine in rural Gambia: A cluster-randomised trial.
PubMed 文献 · Vaccine · 2025-01-10

该4期平行组整群随机试验在冈比亚农村健康婴儿中比较黄热病疫苗与PCV13联合接种或分开接种的免疫应答。联合接种组与分开接种组黄热病中和抗体血清保护率差异的95%CI下限未超过-10%,未证明非劣效,但各组血清保护率均较高,联合接种不影响血清应答。

要点

  • 1+1联合接种组与1+1分开接种组血清保护率差异为-7%(95%CI,-18%至3%),未达非劣效界值。
  • 1+1联合接种组与3+0分开接种组血清保护率差异为4%(95%CI,-10%至15%)。
  • 所有组别黄热病中和抗体滴度≥1:8的比例均较高,联合接种不影响血清应答。

核心结论

  • 未发现黄热病疫苗与PCV13联合接种时血清应答非劣效的证据。
  • 所有组别黄热病中和抗体达到血清保护(滴度≥1:8)的水平均较高。
  • 9月龄时PCV13与黄热病疫苗联合接种不影响黄热病疫苗的血清应答。

研究设计与样本

  • 4期、平行组、整群随机试验,纳入0-10周龄健康婴儿。
  • 随机分配至三组:1+1联合接种组(2剂PCV13方案,9月龄加强剂与黄热病疫苗联合接种)、1+1分开接种组(9月龄PCV13加强剂,10月龄单独接种黄热病疫苗)、3+0分开接种组(标准3剂早期PCV13,9月龄接种黄热病疫苗)。
  • 接种后28-35天采集血样,检测黄热病中和抗体滴度。
  • 3+0分开接种组、1+1联合接种组、1+1分开接种组分别有48、66、98名参与者有中和抗体结果。

主要发现

  • 符合方案分析中,3+0分开接种组、1+1联合接种组、1+1分开接种组及1+1分开接种与3+0分开接种合并组黄热病中和抗体滴度≥1:8的比例分别为81%、85%、92%和88%。
  • 意向性治疗分析结果与符合方案分析相似。
  • 1+1联合接种组与1+1分开接种组血清保护率差异为-7%(95%CI,-18%至3%)。
  • 1+1联合接种组与3+0分开接种组血清保护率差异为4%(95%CI,-10%至15%)。
  • 黄热病疫苗与PCV联合接种或分开接种时,黄热病血清应答无统计学差异。

关键数值与推荐

  • 非劣效界值:联合接种组与分开接种组血清保护率差异的95%CI下限大于-10%时判定为非劣效。
  • 血清保护定义:黄热病中和抗体滴度≥1:8。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Because booster doses of pneumococcal conjugate vaccine (PCV) may be given at a similar time to yellow fever vaccine (YF), it is important to assess the immune response to YF when co-administered with PCV. This has been investigated during a reduced-dose PCV trial in The Gambia. METHODS: In this phase 4, parallel-group, cluster-randomized trial, healthy infants aged 0-10 weeks were randomly allocated to receive either a two-dose schedule of PCV13 with a booster dose co-administered with YF vaccine at age 9 months (1 + 1 co-administration) or YF vaccine administered separately at age 10 months (1 + 1 separate) or the standard three early doses of PCV13 with YF vaccine at age 9 months (3 + 0 separate). Blood samples were collected 28-35 days post-vaccination and YF neutralizing antibody (NA) titres were measured. Proportions with seroprotective YF NA titres ≥ 1:8 were calculated with 95 % confidence intervals (CI). Non-inferiority was demonstrated if the lower limit of the CI for the difference in proportions between the co-administration and separate groups was greater than - 10 %. RESULTS: Forty-eight, 66, and 98 participants enrolled in 3 + 0 separate, 1 + 1 co-administration, and 1 + 1 separate groups respectively had NA results. Per protocol analysis of the 3 + 0 separate, 1 + 1 co-administration, 1 + 1 separate, and the combined 1 + 1 separate and 3 + 0 separate groups found that 81 %, 85 %, 92 %, and 88 % of participants respectively had YF NA titres ≥1:8. Results were similar with analysis by intention-to-treat. The difference in proportions comparing 1 + 1 co-administration and 1 + 1 separate groups was -7 % (95 % CI, -18 % to 3 %). The difference between 1 + 1 co-administration and 3 + 0 separate groups was 4 % (95 % CI, -10 % to 15 %). There was no statistical difference in the YF seroresponse when the YF vaccine was co-administered with PCV or administered separately. CONCLUSIONS: No evidence was found of the non-inferiority of the seroresponse to YF vaccine when co-administered with PCV13. The levels of YF NA attaining seroprotection (NT ≥1:8) were high in all groups. PCV13 co-administered with YF vaccine at 9 months does not affect seroresponse to YF vaccine. http://www.isrctn.org/ - ISRCTN72821613.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Osei I, Schmidt-Chanasit J, Licciardi PV, et al. Immunogenicity of yellow fever vaccine co-administered with 13-valent pneumococcal conjugate vaccine in rural Gambia: A cluster-randomised trial. Vaccine. 2025. PMID: 39798436. doi:10.1016/j.vaccine.2025.126712

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。